Salt AI offers an adaptive, SaaS-based collaborative operating system built for life-science and health-tech enterprises. The platform allows research and clinical teams to rapidly integrate, visualize, and operationalize AI models for tasks such as protein generation, biomarker discovery, clinical evidence synthesis, and diagnostics. With a visual-first interface and enterprise-grade scalability, the product is positioned to shorten R&D cycles and improve cross-functional collaboration in biotech and pharma. The company recently bolstered its leadership with veterans from Boston Consulting Group, Doctor Evidence, Concert AI, and Thermo Fisher Scientific, underscoring its commitment to pair scientific expertise with advanced machine learning. Following a $10 million funding round, Salt AI is scaling its adaptive pipeline across the life-science value chain and preparing demonstrations—such as oncology-focused protein design—at industry events like the 2025 AI Drug Discovery & Development Summit. CEO and co-founder Aber Whitcomb leads the firm’s push to deliver practical AI impact for translational scientists and drug developers. Financial details beyond the latest $10 million infusion, including revenue or user metrics, have not been disclosed.

Total raised

$13M

Funding rounds

2

Latest round

Equity

Latest activity

Sep 2025